Organ toxicity, particularly liver toxicity, remains one of the major reasons for the termination of drug candidates in the development pipeline as well as withdrawal or restrictions of marketed drugs. A screening-amenable alternative in vivo model such as zebrafish would, therefore, find immediate application in the early prediction of unacceptable organ toxicity. To identify highly upregulated genes as biomarkers of toxic responses in the zebrafish model, a set of well-characterized reference drugs that cause drug-induced liver injury (DILI) in the clinic were applied to zebrafish larvae and adults. Transcriptome microarray analysis was performed on whole larvae or dissected adult livers. Integration of data sets from different drug treatments at different stages identified common upregulated detoxification pathways. Within these were candidate biomarkers which recurred in multiple treatments. We prioritized 4 highly upregulated genes encoding enzymes acting in distinct phases of the drug metabolism pathway. Through promoter isolation and fosmid recombineering, eGFP reporter transgenic zebrafish lines were generated and evaluated for their response to DILI drugs. Three of the 4 generated reporter lines showed a dose and time-dependent induction in endodermal organs to reference drugs and an expanded drug set. In conclusion, through integrated transcriptomics and transgenic approaches, we have developed parallel independent zebrafish in vivo screening platforms able to predict organ toxicities of preclinical drugs.
Organ toxicity remains one of the major reasons for the termination of preclinical drug candidates and withdrawal or black box warnings of marketed drugs. Prediction of organ toxicity is limited, as structure-activity relationship rarely exists and hence, in silico modules cannot easily be developed. Although in vitro cell-based assays have been described for preclinical drug toxicity testing (Godoy et al., 2013) , whole organism in vivo models are usually necessary to recapitulate and interrogate the complex multifactorial in vivo events leading to target organ toxicity, including organ-specific biotransformation. The advent of high throughput small molecule library screening has necessitated means to rationalise hits efficiently and with reasonable throughput. Drug candidates most commonly fail because of organ-specific toxicity emphasizing the need for alternative in vivo screening systems offering an adequate throughput whilst capturing systemic toxicity in a multi-organ system. Because screening of lead compounds using higher animal species (rodents and other mammals) is prohibitively expensive, time consuming and limited by compound availability and ethical concerns, an alternative in vivo model that allows rapid, miniaturized, multi-organ toxicity testing is highly desirable. Here, we exploit the zebrafish as an alternative vertebrate model to bridge the gap between simple in vitro cellular studies and in vivo models to predict for multi-factorial or multi-organ events.
The zebrafish model has been recognized as a powerful tool for human disease modeling and drug screening assays (Bugel et al., 2014; Sipes et al., 2011) , based largely on its ease of handling, fecundity, low cost, rapid external development, amenability to genetic manipulation as well as its genetic similarity to higher vertebrates (Lieschke and Currie, 2007) . The larva's small size permits drug screening to be conducted in multi-well plates, compatible with robotic or channel pipetting, both minimizing compound use, and maximizing throughput. The optically translucent larvae, complimented by diverse fluorescent transgenic strains, facilitate direct scoring of organ morphology, and cytological events.
Toxicity screening in the zebrafish system has gained increasing attention recently with an expanded range of compounds tested, coupled with deeper characterization of the molecular response, with a growing molecular, histological, and anatomical characterization of toxicant effects (reviewed in Peterson and Macrae, 2012) . Through 2 main drug metabolism phases, cells biotransform xenobiotics to moieties that are inert or more readily excreted. Phase I modifies compounds by introducing reactive or polar groups, largely through the oxidative action of cytochrome P450 monooxygenases (CYP enzymes). Activated toxicants are then conjugated to small polar endogenous molecules such as glutathione (GSH) via conjugation enzymes including glutathione transferases, with the pool of GSH continually recycled from GSSG via glutathione reductase. Zebrafish possess both biotransformation and detoxification phases (Farber et al., 2001) and have been reported to respond to certain toxicants in a comparable manner to mammals. For example, morphological screening of zebrafish larvae challenged with 31 compounds correctly assigned 87% of known toxic compounds as teratogenic, with low false positive and falsenegative rates (Brannen et al., 2010) . Based on this, a consortium effort has proposed a zebrafish developmental toxicological assay (ZEDTA), with initial phases reporting up to 82% predictive values (Ball et al., 2014) .
To date, zebrafish toxicity assays conducted by ZEDTA and other laboratories has consisted largely of scoring aspects of larval morphology for teratogenic effects (Ball et al., 2014; Padilla et al., 2012; Selderslaghs et al., 2009 Selderslaghs et al., , 2012 Truong et al., 2011) . Organ-specific teratogenic effects have also been assessed through simple morphological examination of the liver (He et al., 2013) , pronephric ducts (Tsay et al., 2007) , heart (including arythmias) (Antkiewicz et al., 2005; Henry et al., 1997; Langheinrich et al., 2003) , ear (Esterberg et al., 2013) , gut peristalsis (Berghmans et al., 2008) , and craniofacial skeleton (Carvan et al., 2004; de Jong et al., 2011) . In some cases, these morphological studies have been complemented by histological examination of the tissues (Driessen et al., 2013; North et al., 2010; Ung et al., 2010) and by the use of tissue-specific stains or antibodies (Daroczi et al., 2006; Farber et al., 2001; Ton et al., 2006) . More recently, cell and tissue-specific fluorescent transgenic fish lines have been employed, which allow facile visualization of the organ/tissue of toxicological interest. These include application of toxicants to transgenic lines marking the liver , the pronephric ducts (Ding and Chen, 2012) , neural tube (Fan et al., 2011; Zhang and Gong, 2013) , gonads (Filby et al., 2014) , muscle (Almeida et al., 2014) , thyroid (Terrien et al., 2011) , heart , and vasculature (Delov et al., 2014) .
Such transgenic "organ" marker lines facilitate automated high-throughput evaluation of drug effects; however such lines still represent only distal toxicological read-outs of organ morphology, and as such, will only identify toxicants that yield overt tissue disruption, nor do they define the molecular signature of each toxicant. Characterization and observation of toxicological responses at a cellular or molecular level may provide a more sensitive and specific readout, without requiring the drug to elicit severe toxic effects. The application of modern transcriptomic approaches to the zebrafish field has led to detailed molecular fingerprinting of the cellular response to drugs or pollutants. Such analyses promise an unparalleled means to determine the mechanism of action of drugs, anchor expression data to toxicity parameters (phenotypic anchoring- Paules, 2003) and identify both broad and specific biomarkers. For example, early microarray experiments identified genes misregulated upon exposure to dioxin species (Andreasen et al., 2006; Carney et al., 2006) . Both larval and adult organ toxicogenomic screens have been performed, analyzing transcriptional effects of heavy metals (Craig et al., 2009; Lam et al., 2006; Ung et al., 2010) , as well as other pollutants (Hermsen et al., 2013; Lam et al., 2013; Yang et al., 2007) , whilst there have been an increasing use of transcriptomics to analyse the response to pharmaceuticals including cyclosporine A, amiodarone, and acetaminophen (Driessen et al., 2015; Hermsen et al., 2012b; van der Ven et al., 2006) . Toxicogenomic signatures derived from zebrafish studies were predictive of the applied chemical (Yang et al., 2007) , whilst comparison of gene expression changes between zebrafish larvae, and in vitro and in vivo rodent and human models challenged with hepatotoxic drugs revealed comparable dysregulation of pathways between models, however, concordance at the single gene level was less pronounced (Driessen et al., 2015) .
Whilst offering detailed read-outs, such molecular identification of cellular detoxification responses is not compatible with routine, high throughput screening of compounds. Ideally, a means to report detoxification pathway activation in the larva would combine the scalability of transgenic larval screening with specific observation of pathway induction. This would inform of proximal toxic response, irrespective of the effect of the toxicant effect on organ morphology/function. Indeed drugs are known to induce detoxification transcripts in zebrafish prior to overt morphological effects (Hermsen et al., 2012a) . To date there have been a number of such zebrafish biosensor lines generated, which report through luciferase or GFP, and are designed largely to respond to environmental estrogens (reviewed in Lee et al., 2015) . These biomarkers were selected through prior knowledge of the effects of the pollutant on specific genes, rather than from unbiased identification. They utilize promoters containing estrogen response elements either placed upstream of minimal promoters (Bogers et al., 2006; Gorelick et al., 2014; Lee et al., 2012) or found endogenously in responding genes such as cyp19a1b (Brion et al., 2012) , choriogeninL (Salam et al., 2008) , or vitellogenin (Chen et al., 2010) . Other biosensor lines utilize promoters of cyp3a65 and cyp1a paralogues, which are upregulated upon exposure to polycyclic aromatic hydrocarbons (Chang et al., 2013; Hung et al., 2012; Kim et al., 2013) , and the hsp70 promoter, activated by heavy metals (Blechinger et al., 2002; Seok et al., 2007) . The latter has been shown to contain electrophile response elements (EpRE), which are bound by the transcriptional activator Nrf2 and are present in the promoters of many other detoxification enzymes including gst, gstp1, and gclc. Indeed a zebrafish gstp1:egfp transgenic line has been shown to report electrophilic alkylating agents in an Nrf2 dependent manner (Tsujita et al., 2011) .
There is a growing acceptance that a general biomarker set of genes, that are all equally regulated by diverse toxicants, does not exist and that toxic compounds regulate common pathways, rather than common genes (Hermsen et al., 2013) . This highlights the need for the development of an array of biomarkers and reporters. To address this need, we used transcriptomic analysis to identify predictive toxicity marker genes from whole larvae and adult liver samples treated with defined hepatotoxic drugs via transcriptomics. A selection of these biomarkers was used to develop a battery of sensitive and specific fluorescent transgenic zebrafish lines able to report cellular toxic load in a dose and temporal specific manner. We thus present an unprecedented integration of toxicogenomic-based gene discovery with transgenic reporter development, providing fluorescent biomarkers developed from unbiased screening. Zebrafish (Danio rerio) used were housed in the IMCB Zebrafish facility. Larvae were obtained through natural crosses and staged as per (Kimmel et al., 1995) . Embryos and larvae were raised and treated in Egg water [60 mg/ml Sea Salt (Red Sea Aquatics, UK)], whilst adults were treated in water from the IMCB main facility.
MATERIALS AND METHODS

Fish Husbandry
Compounds and treatment. Compounds used in this study, and their sources are listed in the following table:
All compounds were dissolved in DMSO, which was diluted in either egg water (larval studies) or facility tank water (adult studies), and used at given LC 50 levels or as indicated. For microarray analysis, the zebrafish adults (6 months old) and larvae (5 dpf) were exposed to reference drugs concentration corresponding to LC 50 values at defined time points. This is determined by incubating zebrafish adults (n ¼ 6-10) and larvae (n ¼ 30-50) with different concentrations of reference drugs (in DMSO stocks) to assess the 50% survival rate of the fish at defined time points at a given concentration. Control fishes and larvae were kept in corresponding 0.01% of DMSO.
Drugs were administered at different concentrations by diluting into the medium for the stated length of time, with control fish given only the corresponding solvent concentration (DMSO; final 0.01%). Drug exposure were performed in 6-well plates (density: 30 larvae per well of 6-well plates) and small size fish tanks (density: 50 ml per adult fish) for larvae and adults, respectively.
Measurement of Compound Concentration in Larvae, Adult Tissues and Media by LC-MS Sample preparation. The isolated zebrafish livers (2-5 as stated) or larvae (50-200) were pooled, weighted (30-50 mg) and added to a 2-ml polypropylene screw cap tube followed by addition of adequate amount of glass beads (0.5 mm, BioSpec Products, Inc.) and potassium phosphate monobasic (KH 2 PO 4 ) buffer (0.1 M, 0.3 ml). The mixture in the tube was disrupted with TOMY Micro smash MS-100 (4500 rpm, 30 s Â 4, the chamber was cooled with dry ice), and added methanol (0.7 ml) and repeated the disruption process (4500 rpm, 30 s Â 4). The tube and culture medium (diluted with methanol, 1:1, v/v) were centrifuged at 20 000 Â g, 4 C, 10 min Â 2 and the supernatants were isolated for LC-MS analysis. If the sample weight was low, the total volume of buffer and solvent (methanol) can be adjusted according to the sample weight, for example, 100 ml for less than 10 mg and 250 ml for 10-20 mg of samples. If the drug concentration was too low (below limit of quantification) in medium because of drug uptake and/or extensive metabolism, the medium would be freeze-dried and the residue was reconstituted in 50% aqueous methanol (1/10 to 1/40 of original volume) by vortexing. For multiple reaction monitoring (MRM) LC-MS/MS analysis, carbamazepine (CBZ) was used as a common internal reference standard (IS) at a final concentration of either 500 nM or 100 ng/ml. A typical MRM sample (100 ml þ single liver) contains the liver, glass beads, KH 2 PO 4 buffer (0.1 M, 20 ml), CBZ IS (2.5 lM or 500 ng/mL, 20 ml in 50% aqueous methanol) and methanol (60 ml), and the final concentration of methanol was about 70% before disruption and centrifugation.
LC-MS methods. The analyses were carried out on a Waters 2795 separation module equipped with PDA detector and ZQ2000 equipped with ESI probe. Samples were resolved on a Phenomenex Luna C18 (2) Normalized concertation or AUC. Normalized concertation in tissue (mmol/kg) ¼ measured concentration (mM)*[sample weight (mg) þ process volume (ml)]/sample weight (mg); where process volume (ml) ¼ buffer volume þ IS volume þ methanol volume. Assuming tissue sample density is near 1, the relative error to total process volume was very small. Normalized AUC (area under the curve) or response (the AUC ratio of sample over IS CBZ) per kg is proportional to concentration and can be calculated similarly:
Normalized AUC or response (per kg) ¼ measured AUC or response Â [sample weight (mg) þ process volume (ml)]/sample weight (mg).
Normalized concertation in medium (mmol/l) or AUC (per liter) was calculated from the measured concertation or AUC by multiplying sample dilution factor or dividing by sample enrichment factor.
Microarray Hybridization and Data Analysis
We used a custom designed zebrafish oligonucleotide microarray set for gene expression profiling (Agilent Technologies; GIS V2; containing 44 000 oligonucleotide probes, 60 mer long; including positive and negative controls designed by Agilent and b-actin controls). The microarray hybridization was performed according to Agilent's One-Color Microarray Based Gene Expression Analysis (Quick Amp Labeling) protocol (Version 5.7, March 2008) and RNA Spike-In-One Color. Prior to labeling, the integrity of all RNA samples was evaluated using Bioanalzer (Agilent 2100 Bioanalyzer system). Larval array analyses used biological quadruplicates of 50 pooled larvae, whilst adult analyses were performed with biological triplicates from pooled liver samples (2 males and 2 females per pool). Arrays were probed using cDNAs reverse transcribed in the presence of Cy3-dUTP using 600 ng of total RNA from either wild-type control or the experimental samples (adult liver or whole larvae). Arrays were hybridized with labeled, denatured probes for about 16 h at 42 C as per Agilent protocol. After hybridization, the slides were washed and scanned for the fluorescence detection using an Agilent DNA Microarray Scanner. Intensity of hybridization to each gene probe was measured using Agilent Feature Extraction Software (v10.5.1.1) and were further analyzed using Genespring software (Agilent Technologies) to obtain normalized expression data. Differentially expressed genes were selected (fold change 2; P-value .01) for further analysis. The extracted datasets were hierarchically clustered and visualized using Tree View Tool (Cluster and Tree View; Eisen et al., 1998) . Genes were annotated using the "Unigene & Gene Ontology Annotation Tool" available at the Genome Institute of Singapore, and were subjected to pathway assembly using Ingenuity Pathway Analysis (IPA; http://www.ingenuity.com; last accessed December 7, 2016). Significance of gene expression changes were determined by ANOVA with post-test. 23 genes were prioritized for further qPCR analysis (cdc34, cyp2aa4, cyp2k18, cyp2n13, dnajb13, fos, gsr, gstt1b, key11, map2k4, mgst1, nfkb2, pik3cg, ppargc1, prdx1, rbp4, rxr, sdr16cs, sqstm1, zgc30, zgc39, zgc88, znf395a).
Reporter transgenics generation. To generate transgene constructs, the promoters of cyp2n13, cyp2k18, gsr, and gstt1b (3.8, 7.3, 2.5, and 2.8 kb, respectively) were cloned into a 5 0 entry clone of the Tol2Kit, and all transgene constructs generated by MultiSite Gateway Three-Fragment Vector Construction Kit (Clontech) using LR Clonase II Plus enzyme (Invitrogen). Plasmid DNA for injection was isolated using HiSpeed Plasmid Midi Kit (Qiagen). FOSMID clones (gsr: CH1073-78P7; gstt1b: CH1073-746D11; cyp2n13: CH1073-39E4; cyp2k18: CH1073-182E22) were ordered from BACPAC Resources Center and modified according to established protocols for fosmid transgenesis (Suster et al., 2011) . Briefly, an itol2 cassette containing Tol2 transposase sites (kanamycin resistant) was recombineered into each fosmid vector. Next, a GFP reporter cassette with ampicillin resistance selection was recombined into the desired fosmid clone downstream of the ATG site of the target gene sequentially using a lambda Red bacteriophage mediated system. The modified fosmid DNA was prepared using Invitrogen HiPure Midiprep kit.
To generate transgenic zebrafish lines, 30 ng/ml plasmid DNA or fosmid DNA and 30 ng/ml tol2 RNA were co-injected into 1-cell stage embryos using a PLI-100 microinjector (Harvard Apparatus).
RNA isolation and qPCR. Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines were adhered to for all real time (RT) qPCR experiments in this study. Whole larvae (n ¼ 15 per sample) or dissected adult livers (2 males and 2 females per sample) were first mechanically disrupted with Trizol reagent (Invitrogen, Carlsbad, California) in Eppendorf tubes using a motorized micropestle (Sigma-Aldrich, Singapore), followed by RNA extraction according to the manufacturer's instruction. RNA concentrations were quantitated using NanoDrop 3300 (Thermo Scientific, Wilmington, Delaware). cDNA is synthesized using Superscript III Reverse Transcriptase (Invitrogen) by first priming a 13-ml reaction that contains 1000 mg of total RNA, 1 ml of Oligo-dT and 10 mM dNTP, which is heated at 65 C for 5 min, before the reverse transcription reaction at 50 C for 1 h followed by 15 min of heat inactivation. qPCR was performed in Bio-Rad MyiQ2. A typical qPCR 20 ul reaction contains 1 ml of cDNA and 10 ml of 2Â KAPA SYBR Fast qPCR Master Mix (KAPPA) where an initial denaturation step at 95 C for 1 min, is followed by 45 cycles of amplification The efficiency (E) of each primer set is determined by
, where slope is the x-value of graph plotted using ct values from serial dilutions of each primer set. The change in ct (Dct) is derived by subtracting the ct value of experimental sets from its control. Relative expression is calculated using E Dct . Fold change of each gene is determined by normalizing it against the reference gene. Fold change was calculated as E Dct gene/E Dct reference gene.
Data were tested for statistical significance with Student's t-test.
Wholemount In Situ Hybridization and Histopathology
All biomarker genes were cloned into pGEM-T easy vector (Promega), and antisense probes were synthesized with T7 DIG RNA labeling kit (Roche) from M13 forward and reverse primers amplified PCR template. Wholemount in situ hybridization (WISH) was performed according to established techniques (Thisse and Thisse, 2008) . Zebrafish larvae and adult liver for histology were fixed in Davidson's fixative, processed by routine histology techniques for paraffin embedding performed on the Sakura Tissue-Tek VIP 5 and the Sakura Tissue-Tek VIP 6, and sectioned at approximately 5 mm, and stained with hematoxylin and eosin (H&E) using a Leica AutoStainer XL Automated Slide Stainer and coverslipped using a Leica CV5030 Robotic Coverslipper.
Imaging. Fish larvae or adults were anaesthetized with 16.8 mg/ ml tricaine solution (buffered to pH 7.0) and mounted either in 1% low melting agarose for confocal imaging on a Zeiss LSM700 or in 3% methyl cellulose for imaging on a Leica MZ16FA. Twenty to forty larvae were assessed for WISH and transgenic analyses. Representative micrographs for liver lesions were taken using an Olympus Digital Microscope camera DP71.
RESULTS
Through LC-MS analysis we have shown that the hepatotoxicants, amiodarone, diclofenac, and flutamide, are readily taken up by whole larvae and adult livers (Poon et al., 2016) . In adult zebrafish liver, there was significant uptake of amiodarone, diclofenac, and flutamide within 3 h of exposure, with a concomitant measurable reduction from the medium over the 24 h of exposure noted for amiodarone and flutamide ( Supplementary Figure 1) , indicating accumulation of the drug within the tissues. We thus selected these 3 drugs as a reference set for further characterization of toxicity response.
For all subsequent analyses, we exposed the adult fish (6 months) or larvae (5 dpf) to the LC 50 concentration corresponding to that drug and exposure duration (Poon et al., 2016) . For zebrafish larvae, exposure to LC 50 concentrations of all 3 drugs elicited abnormal morphology including bent bodies, with blood flow often reduced. In addition, amiodarone, an antiarrhythmic drug, induced irregular heart rate (data not shown). For adult zebrafish, swimming ability was affected with increasing dosage of any of the 3 drugs, to a point where they became immotile.
To determine if the selected DILI drugs induced hepatic injury comparable to mammals, we performed histopathology analysis. After 24 h of exposure to amiodarone or diclofenac, intracytoplasmic eosinophilic inclusions and vacuoles were detected in sections of 6 dpf larval liver (Supplementary Figure  2A-D) . Similar hepatic injury leading to cellular necrosis was also observed in diclofenac and flutamide treated adults (Supplementary Figure 2I-L) . In addition, in histological sections of amiodarone-treated larvae, sloughing of intestinal epithelium was observed, indicating intestinal injury. This was not observed for the other 2 drugs (Supplementary Figure 2E-H) . Taken together, our results confirmed that the DILI drugs tested in this study cause organ damage, supporting the use of zebrafish for analysis of genome-wide transcriptomics response to DILI compounds.
To identify organ toxicity biomarkers encompassing both early and late responses, custom designed zebrafish microarrays (GIS v2) were used to compare the transcriptomes of adult livers (triplicates, each containing 2 male and 2 female livers) at 3 time points (3, 12 and 24 h) following exposure to LC50 concentrations of reference drugs (amiodarone, diclofenac or flutamide). We did not separate the genders as we wanted to observe robust responding genes for both genders. Drug treated samples showed clusters of differential transcript expression compared with controls. The top fifty most highly induced genes (fold change 2 and P < .01) for each drug are presented as heat maps (Supplementary Figure 3) ; the full list of up-regulated genes in the adult liver for each time point and drug are presented in Supplementary Tables 1-3 . Shared and unique transcriptional responses of livers to the 3 drugs across the 3 time points are represented by a Venn diagram (Supplementary Figure 3) . We found 31 genes that were significantly upregulated at all time-points in the zebrafish adult liver following treatment with all 3 reference compounds. The expression profiles of these 31 genes are presented as a heat map (Supplementary Figure 3; annotated in Supplementary Table 4) . As previously observed (Hermsen et al., 2013) , each drug does not lead to a uniform transcriptional response, but rather invokes a unique signature. The overlap between amiodarone and diclofenac was stronger than between either and flutamide.
Because the aim of this study was to identify biomarkers for generation of reporter transgenics that could be used for compound screening in zebrafish larvae following exposure for a variety of durations, we proceeded additionally to determine the transcriptomics of larvae exposed to the reference DILI drugs set for 3 and 24 h by microarray analysis. The Venn diagram ( Figure 1 , upper panel) presents the number of genes uniquely or commonly upregulated (expression level: fold change 2 and P < .05) by the 3 drugs at both time points (annotated in Supplementary Tables 5-7 ). The 64 genes that are commonly upregulated by all 3 drugs are presented as a heatmap (Figure 1, lower panel) , with the complete list of up-regulated genes presented in Supplementary Table 8 .
Annotation of common genes identified in drug-challenged zebrafish adults and larvae suggests an enrichment of genes involved in detoxification and stress response. Through canonical pathway analysis as well as IPA, 4 pathways (NRF2-mediated Oxidative stress response, glutathione-mediated detoxification, xenobiotic metabolism signaling, and aryl hydrocarbon receptor metabolism signaling) were identified as being significantly enriched in both adult liver larvae (Supplementary Figure 4) . We also noted that the NRF2 signaling pathway is significantly dysregulated at multiple timepoints in adult liver (Supplementary Figure 5) . Consistent with the liver being the major site of detoxification, the stress responsive pathways were significantly enriched in the liver compared with the whole larvae.
Based on the robustness of response revealed by microarray analysis in adult livers, coupled with comparable response in larvae, we prioritized 23 genes for further analysis by qPCR. Of these, 4 potential biomarkers were selected for generation of transgenic reporter lines, as qPCR analysis indicated they were consistently induced by different compounds (data not shown) and represented both detoxifications Phases 1 and 2. Cytochrome P450 family 2 subfamily K polypeptide 18 (cyp2k18), cytochrome P450 family 2 subfamily N polypeptide 13 (cyp2n13), glutathione s-reductase (gsr), and glutathione S-transferase theta 1b (gstt1b) play a role in either of the 2 phases of drug metabolism. Amiodarone and diclofenac induced higher biomarker expression in the adult liver than flutamide, with diclofenac inducing rapidly at 3 and 12 hpe. cyp2k18 responded most strongly followed by gstt1b upon amiodarone and diclofenac induction. cyp2k18 also responded to flutamide induction more efficiently than the other biomarkers, with cyp2n13 showing the lowest induction amongst those genes (summarized as an expression matrix, Figure 2A ). Quantitative PCR (qPCR) confirmed upregulation of selected genes in the drug challenged transcriptomes (Supplementary Table 9 ). To characterize these biomarkers further, we determined their temporal-spatial expression in unchallenged larvae during development by whole mount in situ hybridization (WISH). All 4 genes, cyp2n13, cyp2k18, gstt1b, and gsr, were undetectable throughout larval development until 5 dpf when very weak expression of all genes were observed in the larval liver and gastrointestinal (GI) tract. To define the spatial induction patterns of these biomarkers upon exposure, 5 dpf wild-type larvae were treated with diclofenac for 24 h, and then processed for WISH. Robust RNA accumulation of all 4 genes was observed, primarily in the GI tract ( Figure 2B-M) . cyp2k18 and gstt1b were the most highly induced among the 4 genes selected, with visible but lower induction of gsr and cyp2n13. In the highly induced larvae, enhanced signal can also be observed in the liver ( Figure 2K ).
To establish a rapid, screenable readout of toxicity, we generated transgenic reporter lines using the cis-regulatory regions   FIG. 2 . Microarray results of selected biomarkers and confirmation by whole mount in situ hybridization. A, Expression matrix summarizing the microarray behaviour of 4 selected biomarkers, cyp2n13, cyp2k18, gsr, and gstt1b, in whole larvae (E) and adult livers (A) at given exposure times for each of the DILI drugs (grey to red represents graded low to high expression). B-M, Wholemount in situ hybridization (WISH) of 5 dpf wildtype larvae incubated in either DMSO (CTRL; B-E, J, L) or diclofenac (Dic; F-I, K, M) for 24 h at LC50 concentration before being processed for WISH using DIG labeled probes targeting reporter genes-gstt1b (B, F, J, K), cyp2k18 (C, G, L, M), gsr (D, H) and cyp2n13 (E, I). Overview images of equally treated larvae display consistency of the response (B-I), whilst the magnified images of larvae body shows the significant upregulation occurring in intestine and liver by gstt1b (K) and cyp2k18 (M) probes upon diclofenac exposure compared with the noninduced control larvae (J, L). Abbreviations: I, intestine; L, liver; Y, yolk.
of these biomarkers to drive egfp expression. We initially isolated short promoters comprising the 7.3, 3.8, 2.5, and 2.8 kb upstream of cyp2k18, cyp2n13, gsr, and gstt1b transcription start sites, respectively. These were cloned in front of egfp in a vector including flanking Tol2 sites (Balciunas et al., 2006) . Upon injection of all 4 constructs, we noted transient mosaic expression throughout the whole larvae. After raising and breeding injected embryos, we could not identify founders expressing eGFP for Tg(gstt1b:egfp), either basally or upon exposure to drugs, whilst all Tg(gsr:egfp) founders showed highly variable eGFP expression patterns, possibly because of position effects associated with random genomic integration of the transgene construct. In contrast, we identified 4 Tg(cyp2k18:egfp) founders, none of which showed expression at 2 dpf, but were detectable at low levels in the intestinal region of the larvae from 5 dpf onwards ( Figure 3A ). This correlates with the low levels of cyp2k18 expression observed from the WISH data ( Figure 2L) . Similarly, Tg(cyp2n13:egfp) displayed low eGFP fluorescence in the intestinal bulb region in 5 dpf larvae, consistent with endogenous cyp2n13 expression ( Figure 2E ).
Given the strong concordance of the cyp2n13:egfp and cyp2k18:egfp transgenic expression patterns with those of their respective endogenous genes, we tested if both would show induction of eGFP upon exposure to the reference drug set. Treatment of the Tg(cyp2n13:egfp) lines with diclofenac at 5 dpf for 24 h failed to elicit a measurable induction of eGFP fluorescence, despite potent induction of endogenous cyp2n13 transcription. In contrast, when we exposed 5 dpf Tg(cyp2k18:egfp) larvae from 8 independent lines to diclofenac for 24 h, we observed a strong enhancement of fluorescence intensity in the GI tract of the larvae ( Figure 4C compare with Figure 4A ), thus validating the overall approach. For each construct, multiple insertion lines were screened and tested for induction (Supplementary Table 10) .
We surmised that the failure of Tg(gstt1b:egfp), Tg(gsr:egfp), and Tg(cyp2n13:egfp) to be expressed as predicted, could be because of the absence of more distally located, critical basal and/or inductive enhancers in these promoter fragments. To circumvent this potential shortcoming, we opted to surround egfp with additional flanking sequence of each gene by fosmid transgenesis employing RedET recombineering (Ciotta et al., 2011) . Fosmid clones for gsr, gstt1b, and cyp2n13 were engineered by placing egfp at the translation start site for all 3 genes ( Figure 3B ; gene structure and accession numbers for all 3 reporter genes are presented in Supplementary Table 11 ). To enhance genome integration mediated by Tol2 transposase, inverted Tol2 LTRs (long-terminal repeats) were recombined into the fosmid vector (Suster et al., 2011) . Mosaic eGFP expression throughout the larvae was observed upon injection of each modified fosmid construct. We selected eGFP-positive F0 of the 3 fosmid transgenics for propagation and identified founders transmitting each fosmid transgene, documenting the expression patterns in F1s (Supplementary Table 10) .
Unexpectedly, the TgFOSMID(cyp2n13:egfp) lines directed low levels of expression of eGFP beyond the endogenous expression domains observed by WISH as well as by the short promoter Tg(cyp2n13p:egfp) lines, including the heart, olfactory bulb, cloaca, skin, intestinal bulb and liver in 5 dpf larvae (Supplementary Figure 6b) . TgFOSMID(gsr:egfp) exhibited the earliest and widest eGFP expression observed from 2 dpf faintly in the heart, forebrain, and skin and extending to the olfactory bulb, kidney, intestinal bulb, and liver by 5 dpf ( Figure 3B ). The expression was not as varied as that driven by the short promoter Tg(gsr:egfp) transgenic lines, suggesting inclusion of insulator elements in the fosmid reduced integration site variability. Finally, TgFOSMID(gstt1b:egfp) showed no expression at 2 dpf, but weak expression in the lens and the skin by 5 dpf ( Figure 3B ). Lens expression of gstt1b was not observed by WISH.
We established multiple independent lines for each transgene in the subsequent F2 generation to test for drug induction. Treatment of thirty independent lines of TgFOSMID(cyp2n13:egfp) with any of the 3 reference drugs failed to elicit a noticeable increase in fluorescence (Supplementary Figure 6) , and these transgenics were not pursued further. In contrast, the 5 TgFOSMID(gsr:egfp) and 5 TgFOSMID(gstt1b:egfp) transgenic lines all exhibited a robust induction of eGFP by the reference drugs at 24 hpe, with TgFOSMID(gsr:egfp) induction generally stronger ( Figure 4I -L, Q-T). Increased fluorescence was readily observable at 18 hpe in the GI tract and to a lesser extent, in the liver of these transgenes and thus was comparable to the response by Tg(cyp2k18p:egfp). Additionally, we noted that TgFOSMID(gsr:egfp) showed weak induction throughout the body. We selected the 2 best responding lines per transgene for further propagation and analysis.
To determine whether the generated lines would also respond to a broader compound spectrum, we tested our 6 responding lines to a larger battery of DILI drugs including troglitazone, rosiglitazone, APAP (acetaminophen), and the Roche compound (ROXXXXX53) (Figure 4 ). The intensity of the induction were determined (Supplementary Table 12 ) and found to vary with both the promoter used and compound tested, but was always strongest in the GI tract, with weaker induction in the liver.
Of the 3 lines, Tg(cyp2k18:egfp) showed the most robust induction, especially to amiodarone, troglitazone, rosiglitazone, diclofenac and R0XXXXX53, with weaker induction to APAP and flutamide. Similarly, TgFOSMID(gsr:egfp) responds well to APAP, amiodarone, diclofenac, and trosiglitazone, but less well to flutamide, rosiglitazone and R0XXXXX53. TgFOSMID(gstt1b:egfp) responded most strongly to diclofenac, however, the overall response of this line to the other drugs is low, and we consider this line to be the least responsive. The results show that diclofenac elicited the highest response in all 3 transgenic lines, which mirrored the strong transcriptional effect of this drug revealed by microarray analysis, and are in line with the observed fast metabolism and depletion of GSH because of the formation of active metabolite(s) (Poon et al., 2016) . Of the extended set, the thiazolidinediones (troglitazone and rosiglitazone) induced most strongly. Tg(cyp2k18:egfp) and TgFOSMID(gstt1b:egfp) were barely induced by APAP, which did induce TgFOSMID(gsr:egfp).
We noted that the extent of eGFP expression along the GI tract was not uniform for all treatments and all transgenes, however, posterior extent of expression generally correlated with intensity of response. For example, Tg(cyp2k18:egfp) showed bright fluorescence the entire length upon challenge with amiodarone, yet only low level induction with APAP, which was limited to the anterior.
Our transgenic lines permitted us to monitor the real-time dynamics of in vivo induction through time-lapse video microscopy. We imaged 5 dpf Tg(cyp2k18:egfp) larvae challenged with diclofenac, and observed an anterior to posterior wave of induction along the GI tract, reaching saturation by 12 h post exposure ( Figure 5 ; Supplementary Movie 1). We also imaged the induction dynamics of this transgene upon challenge with 5 mM APAP to ascertain if there is a compartmentalization of response to different drugs. We found that there was only a muted response to APAP over time which was only visible in the anterior region (Supplementary Movie 2 and Supplementary  Figure 7) . FIG. 3 . Generation of biomarker reporter transgenic lines and background expression in untreated larvae. Schematic representation of constructs used for the generation of eGFP tagged transgenics by promoter cloning or fosmid recombineering. A, 7.3 kb of sequence upstream of cyp2k18 translation start site was fused in front of egfp and a polyA signal. There was no eGFP expression in untreated 2 dpf Tg(cyp2k18:egfp) larvae, but low expression in the GI tract at 5 dpf (lower panels). B, The fosmid clones for gsr (CH1073-78P7) and gstt1b (CH1073-746D11) were modified through 2 recombineering events, introducing inverted Tol2 LTRs to the fosmid vector and egfp in frame immediately after the start codon of the respective gene. Total fosmid size, gene orientation and the exon (e) where the transcription start site and egfp are positioned is indicated. Fluorescent micrographs of TgFOSMID(gsr:egfp) and TgFOSMID(gstt1b:egfp) showing broad low level expression of TgFOSMID(gsr:egfp) at 2 dpf, becoming more restricted to the GI tract by 5 dpf (lower panels). eGFP expression was not observed at 2 dpf in the TgFOSMID(gstt1b:egfp) line, but showed weak lens and skin expression at 5 dpf (lower panels). To test the sensitivity of Tg(cyp2k18:egfp), we tested its response to a range of concentrations of amiodarone and diclofenac ( Figure 6 ) applied for 24 h. We observed a dose dependent increase in fluorescence intensity with high sensitivity that is responsive to concentrations 10Â lower than the determined LC50 values. The intensity of induction from anterior to posterior region of the GI tract correlated to the increasing dose of both compounds used, with anterior induction only noted in the lower concentrations. At these concentrations, the fish showed limited adverse effects, underlining the high sensitivity and potential utility of these transgenics.
DISCUSSION
A number of DILI causing drugs are known to induce comparable responses in zebrafish including acetaminophen, amiodarone, chlorpromazine, tetracycline, cyclosporine A, and valproic acid (Driessen et al., 2013; He et al., 2013; Raldua and Pina, 2014) . For the drugs we tested, we also observed lethality and cytological toxicity by histology, underscoring conserved responses to toxicants in fish. Based on the absorption, toxicity, and histological analyses (this manuscript and Poon et al., 2016), we selected reference DILI compounds for unbiased transcriptomic identification of biomarkers of the detoxification process. This identified upregulation of genes implicated in all detoxification phases, including Phase 1 biotransformation Cytochrome P450 (CYP) enzymes, Phase 2 conjugating enzymes, and excretory transporter systems, which have been observed in similar previous transcriptomic analyses of toxic stress (Driessen et al., 2015; Hermsen et al., 2012b Hermsen et al., , 2013 Ung et al., 2010) . Identification of a stimulated multiphased response further underscores the conservation to mammalian detoxification. Of particular note, the Nrf2 pathway, central to the regulation of the toxic response, was modulated at multiple nodes by all 3 drugs. Surprisingly, whilst all drugs induced the same overall detoxification pathways, each drug and exposure duration elicited a unique profile of specific gene induction. This has been noted before in zebrafish hepatotoxicity analyses, and advocates the use of a battery of biomarkers in determining toxic responses (Driessen et al., 2015) .
Whilst qPCR can be used to validate hits, we also employed WISH as this affords simultaneous spatiotemporal visualization of the response of all larval organs, as well as assaying response robustness through parallel screening of multiple larvae. Such detailed and comparative analyses are not feasible in other systems and spatial expression assays have not been utilized extensively in zebrafish toxicity studies to date, although WISH has been shown to validate transcriptomic analyses (Blechinger et al., 2002; Yang et al., 2007) . It offers a means to elucidate mechanisms of actions or study additional markers not covered by the existing reporter lines. WISH is, however, impractical for rapid screening of many drugs which is better suited to fluorescent imaging. One particular advantage of a fluorescent readout of toxicity for screening is compatibility to computational segmentation, permitting automated processing and statistical analysis. Alternatively, replacement of eGFP with other fluorophores such as luciferase may also be used to quantitate responses. Other flurophores such as mCherry would reduce signal overlap with gut autofluorescence which can be an issue with eGFP. Alternatively, use of a narrow band-pass filters and confocal imaging can also mitigate autofluorescence issues (North, 2006) . Based on our microarray, qPCR and in situ analyses, we prioritized gsr, gstt1b, cyp2k18, and cyp2n13 as candidate biomarkers, providing both Phases 1 and 2 representation. The conservation of the CYP enzymes between zebrafish and humans is complex and subfamily dependent. In particular, xenobiotic metabolizing families CYP 1-4 show lineage specific expansion and diversification. Zebrafish cyp2n13 shares synteny with human cyp2j2, which has been shown to be active in the firstpass metabolism of several antihistamine drugs, such as terfenadine, astemizole, and ebastine in human liver microsomes (Lee et al., 2010; Liu et al., 2006; Matsumoto et al., 2002) . Zebrafish cyp2k18 in turn is most homologous to human cyp2w1, recently employed as a cancer prognostic marker because of its induction during colon cancer (Edler et al., 2009; Karlgren et al., 2006) and hepatocellular carcinoma . gsr is an important glutathione recycling gene involved in cellular glutathione redox status while gstt1b is a soluble form of GST which is involved in endobiotic metabolism. All 4 genes were shown to be expressed in embryonic zebrafish using transcriptome microarrays (Goldstone et al., 2010; Timme-Laragy et al., 2013) .
Using short upstream promoter regions of these genes, our first attempts to make eGFP reporter lines were mostly unsuccessful, with the exception of the 7.3kb cyp2k18 promoter. We thus utilized fosmid transgenesis, which yielded 2 more responsive biomarker lines, suggesting basal or inducible enhancers lie at a distance from the transcription start site of certain members of the detoxification response. We were surprised that no TgFOSMID(cyp2n13:egfp) lines were induced by our reference FIG. 6 . Dose-response of the Tg(cyp2k18:egfp) reporter line. Micrographs of the lateral GI tract of Tg(cyp2k18:egfp) at 6 dpf showing increased fluorescence intensity with increasing diclofenac (ai-av) and amiodarone (bi-bv) concentration at 24 hpe. The reporter is responsive to drug concentration 10 times lower (aiii and biii) than LC50 concentration (av, diclofenac, 1 mM; bv, amiodarone, 5 mM).
drug set, despite upregulation of the endogenous RNA observed by in situ, microarray and qPCR. This may indicate an inductive enhancer is located beyond the 37 kb flanking DNA, and cautions that detoxification genes might be subject to very long range regulation.
Notably, we have demonstrated these lines to be sensitive to 5-to 10-fold less drug than LC50, critical for high throughput screening where the toxicity level is unknown. Furthermore, each transgenic line responded differently to each drug. For example, we observed that APAP strongly induced the TgFOSMID(gsr:egfp) line whilst the Tg(cyp2k18:egfp) and TgFOSMID(gstt1b:egfp) lines barely responded. This contrasts with the effect of other drugs that elicited response in all 3 lines, but it might reflect the response to the fast and significant depletion of GSH ( Figure 3D ; see also Poon et al., 2016) because of the formation of conjugate of GSH and active metabolite. This is interesting given the importance of replenishment of GSH upon APAP overdosing and the central role of GSR in GSH regeneration (North et al., 2010) . Moreover, this highlights the importance of using multiple transgenic reporters in such screens.
We noted that the 4 biomarkers were all highly induced in the GI tract in the larvae, more than in the liver. This has also been noted in other larval biomarker expression analyses (Chang et al., 2013) . We suggest this potentially highlights the GI tract as the primary detoxification organ in the larval fish. If this was simply because of being the site of maximal exposure, one would expect the epidermis to also be strongly responsive, however, we do not observe this, arguing that the GI tract responds uniquely. It is likely that the liver plays a central role in detoxification of the blood stream in adults. Indeed, elegant mouse experiments have concluded that intestinal Cytochrome P450 is responsible for first-pass metabolism of oral dosed drugs, whilst the liver P450 enzymes are responsible for clearing systemic toxins (van Herwaarden et al., 2007) .
Furthermore, strong inductions were observed along the entire GI tract, whilst weaker inductions appeared to be restricted to the anterior region. We interpret this to be a function of tissue density/volume and the brightest response was seen anteriorally. This is supported by a graded anterior restriction of visible fluorescence upon administration with drug dilutions. Alternatively low levels of drug may be metabolized and absorbed by the anterior GI tract and not available for the posterior. We see no evidence from our transgene studies to conclude that the transgenes are inherently regionalized in their response within the GI tract, nor that a particular drug elicits a response only in one region.
In conclusion, through combined transcriptome biomarker identification and subsequent fluorescent reporter transgenesis, we generated 3 zebrafish reporter lines for screening of preclinical drug toxicity. These add to the growing list of transgenic toxicant biomarkers, but are the first to be identified through unbiased transcriptomic surveys. The discovery of novel biomarkers in this study not only enables the development of preclinical screening tool but also improve our understanding of the dynamics of drug metabolism in zebrafish.
SUPPLEMENTARY DATA
Supplementary data are available at Toxicological Sciences online.
